Antidiabetic medications in overweight/obese patients with type 2 diabetes: Drawbacks of current drugs and potential advantages of incretin-based treatment on body weight

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 154, 2007, Pages 19-28

  Bonora, E ^a,b  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; INCRETIN;

ABDOMINAL PAIN; ADD ON THERAPY; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; METABOLIC REGULATION; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; OBESITY; OVERWEIGHT; WEIGHT GAIN;

EID: 34250636401     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01441.x     Document Type: Review

References (115)

1. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol 1981 113 : 144 56.
2. Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham study. Am J Epidemiol 1981 114 : 697 704.
3. Bonora E, Kiechl S, Willeit J et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004 53 : 1782 9.
4. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
5. Tuomilehto J, Lindstrom J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344 : 1343 50.
6. Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 2001 24 : 1522 7.
7. Bonora E, Targher G, Formentini G et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004 21 : 52 8.
8. Bonora E, Bonadonna RC, Del Prato S et al. In vivo glucose metabolism in obese and type 2 diabetic subjects with or without hypertension. Diabetes 1993 42 : 764 72.
9. Bonadonna RC, Groop L, Kraemer N et al. Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990 39 : 452 9.
10. Bonora E, Del Prato S, Bonadonna RC et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992 41 : 1151 9.
11. Ward WK, Beard JC, Halter JB et al. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 1984 7 : 491 502.
12. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988 318 : 1231 9.
13. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999 104 : 787 94.
14. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferators-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004 89 : 463 78.
15. Ahima R. Adipose tissue as an endocrine organ. Obesity 2006 14 (Suppl. 5 242S 9. E, Zenere M, Branzi P et al. Influence of body fat and its regional localization on risk factors for atherosclerosis in young men. Am J Epidemiol 1992 135 : 1271 8.
16. Bonora E, Targher G, Branzi P et al. Cardiovascular risk profile in 38-year-old men. Contribution of body fat content and regional fat distribution. Int J Obes Relat Metab Disord 1996 20 : 28 36.
17. Bonora E, Targher G, Zenere MB et al. Obesity worsens cardiovascular risk profiles independently of hyperinsulinaemia. J Intern Med 1997 241 : 463 70.
18. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 47 : 1643 9.
19. Bonora E, Kiechl S, Willeit J et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003 27 : 1283 9.
20. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005 28 : 1769 78.
21. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006 38 : 64 80.
22. Toft I, Bonaa KH, Ingerbretsen OC et al. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol 1997 17 : 553 9.
23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999 19 : 972 8.
24. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004 24 : 29 33.
25. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease. Am J Physiol Heart Circ Physiol 2007 292 : H1655 H1663.
26. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983 67 : 968 77.
27. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990 322 : 882 9.
28. Larsson B, Svardsudd K, Welin L et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984 288 : 1401 4.
29. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 52.
30. Pettitt DJ, Lisse JR, Knowler WC, Bennett PH. Mortality as a function of obesity and diabetes mellitus. Am J Epidemiol 1982 115 : 359 66.
31. Chaturvedi N, Fuller JH. Mortality risk by body weight and weight change in people with NIDDM. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1995 18 : 766 74.
32. Zoppini G, Verlato G, Leuzinger C et al. Body mass index and the risk of mortality in type II diabetic patients from Verona. Int J Obes Relat Metab Disord 2003 27 : 281 5.
33. Carr DB, Utzschneider KM, Hull RL et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004 53 : 2087 94.
34. Bonora E, Targher G, Formentini G et al. The metabolic syndrome is an independent predictor of cardiovascular diseases in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004 21 : 52 8.
35. Lean ME, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990 7 : 228 33.
36. Williamson DF, Thompson TJ, Thun M et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000 23 : 1499 504.
37. American Diabetes Association. Standard of medical care in diabetes - 2006. Diabetes Care 2006 29 (Suppl. 1 S4 42.
38. IDF Clinical Guidelines Task Force. Global guidelines for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 23 : 579 93.
39. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
40. Wing RR, Koeske R, Epstein LH et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987 147 : 1749 53.
41. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type 2 diabetic patients, UKPDS Group. Metabolism 1990 39 : 905 12.
42. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obese Relat Metab Disord 1992 16 : 397 415.
43. Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med 1993 119 : 722 6.
44. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical Guidelines for the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, MD : US Department of Health and Human Services, Public Health Service, NIH, NHLBI, 1998.
45. Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000 2 : 121 9.
46. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003 63 : 1165 84.
47. Hauner H. Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol 2004 3 : 223 32.
48. Klein S, Sheard NF, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. Diabetes Care 2004 27 : 2067 73.
49. Aucott L, Poobalan A, Smith WCS et al. Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes - a systematic review. Diabetes Obes Metab 2004 6 : 85 94.
50. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997 20 : 1744 66.
51. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 281 : 2005 12.
52. Manning RM, Jung RT, Leese GP et al. The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up. Diabet Med 1998 15 : 497 502.
53. Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001 9 (Suppl. 4 348S 53. RR, Marcus MD, Epstein LH et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987 10 : 563 6.
54. Kahn MA, Peter JV, Breen GA et al. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppression. Obes Res 2000 8 : 43 8.
55. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006 295 : 761 75.
56. VanGaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 97.
57. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 61.
58. Finer N, Bloom SR, Frost GS et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2000 2 : 1 8.
59. Berne C, the Orlistat Swedish Type 2 diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005 22 : 612 8.
60. Derosa G, Cicero AF, Murdolo G et al. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 2004 17 : 222 9.
61. Halpern A, Mancini MC, Suplicy H et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 5 : 180 8 DE, Bray GA, Pi-Sunyer FX et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 25 : 1033 41.
62. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006 368 : 1660 72.
63. Norris SL, Zhang X, Avenell A et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Arch Intern Med 2004 164 : 1395 404.
64. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002 287 : 360 72.
65. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus. Treat Endocrinol 2003 2 : 33 47.
66. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005 65 : 385 411.
67. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.
68. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 283 : 1695 702.
69. Mäkimattila S, Nikkilä K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999 42 : 406 12.
70. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 65.
71. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type 2 non-insulin-dependent diabetes. Obes Res 1998 6 : 47 53.
72. Breuer HW. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003 41 : 421 40.
73. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 32 : 837 53.
74. Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: a comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001 24 : 983 8.
75. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide vs. glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999 43 : 155 66.
76. Rosenstock J, Hassman DR, Madder RD et al. Repaglinide vs. nateglinide monotherapy. Diabetes Care 2004 27 : 1265 70.
77. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? (Editorial). N Engl J Med 2006 355 : 2477 80.
78. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular event in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005 366 : 1279 89.
79. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006 368 : 1096 105.
80. Adams M, Montaque CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997 100 : 3149 53.
81. Boden G, Homko C, Mozzoli M et al. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005 54 : 880 5.
82. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001 86 : 280 8.
83. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetes patients. J Clin Endocrinol Metab 2002 87 : 2784 91.
84. Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes 2000 24 (Suppl. 2 S32 5.
85. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
86. Raskin P, Allen E, Hollander P et al. INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
87. Rosenstock J, Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005 143 : 549 58.
88. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 : 2929 40.
89. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004 13 : 1091 102.
90. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006 15 : 431 42.
91. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006 60 : 1454 70.
92. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 : 1696 705.
93. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006 29 : 435 49.
94. Buse JB, Henry RR, Han J et al. for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 35.
95. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 100.
96. Kendall DM, Riddle MS, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 : 1083 91.
97. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006 8 : 436 47.
98. Nauck MA, Hompesch M, Filipczak R et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006 114 : 417 23.
99. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subject with type 2 diabetes. Diabetes 2006 55 (Suppl. 1 A27 (Abstract 115-OR).
100. Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
101. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 49 : 2564 71.
102. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 5.
103. Ahrén B, Pacini G, Foley J et al. Improved meal-related β-cell function and insulin sensitivity by the dipetidyl peptidase IV inhibitor vildagliptin in metformin- treated patients with type 2 diabetes over 1 year. Diabetes Care 2005 28 : 1936 40.
104. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 43.
105. Mari A, Sallas M, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 90 : 4888 94.
106. Radikova Z, Azuma K, Thomas E et al. Effects of vildagliptin on postprandial glucose homeostasis in type 2 DM. 42nd Annual Meeting of the European Association for the Study of Diabetes. Copenhagen, Denmark and Malmoe, Sweden, 2006, 14-17 September (Abstract 0660).
107. Kelley DE, Azuma K, Radikova Z et al. Effects of vildagliptin on glucose and lipid oxidation in patients with type 2 diabetes (T2DM). Diabet Med 2006 23 (Suppl. 4 253 (Abstract A686).
108. Ahrén B, Landin-Olsson M, Jansson P-A et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 2078 84.
109. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of beta-cell proliferation and inhibition of apoptosis. Endocrinology 2003 144 : 5145 8.
110. Duttaroy A, Voelker F, Merriam K et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. Diabetes 2005 54 (Suppl. 1 A141 (Abstract 572-P).
111. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozocin-induced diabetic rats. Diabetes 2003 52 : 741 50.
112. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 28 : 1556 68.
113. Foley JE, Dejager S, Chang I, Schweizer A. Effect of vildagliptin monotherapy on body weight in drug-naïve patients with type 2 diabetes (T2DM). 19th International Diabetes Federation Congress. Cape Town, South Africa, 2006, 3-7 December (Abstract 826).
114. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1) : A29 (Abstract 120-OR).
115. Nathwani A. The Use of Vildagliptin for Treatment of Patients with Type 2 Diabetes Mellitus. Washington, DC : Presented at American Diabetes Association - 66th Scientific Sessions, 2006.